Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited disclaim responsibility for the contents of the related announcement, and no liability is assumed for any loss arising from its use or reliance.

Shandong Xinhua Pharmaceutical Company Limited (Stock Code: 00719) signed an equity acquisition intention agreement on 9 December 2024 with NovoSana (Europe) B.V. After further discussions and negotiations, neither party reached a consensus on the final terms. Consequently, the project will not proceed, and the agreement has been terminated.

According to the Company, the termination will not affect ongoing production or operations and does not prejudice the interests of the Company or its shareholders. Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.

As of 6 February 2026, the board of Shandong Xinhua Pharmaceutical Company Limited comprises Executive Directors Mr. He Tongqing (Chairman), Mr. Xu Wenhui, and Mr. Hou Ning; Independent Non-executive Directors Mr. Pan Guangcheng, Mr. Zhu Jianwei, Mr. Ling Peixue, and Ms. Cheung Ching Ching, Daisy; and Non-executive Directors Mr. Xu Lie and Mr. Zhang Chengyong.